agilon health (AGL) Earnings Date & Reports

Key Takeaways

• agilon health guided Q1 2026 revenue at $1.35 billion to $1.39 billion, aligning closely with analyst consensus of $1.38 billion from 16 analysts.
• Company expects adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $35 million to $45 million, marking the first positive quarter.
• Medical margin projected at $115 million to $130 million, a sharp improvement from Q4 2025's negative $74 million.
• Total membership guided at 536,000 to 551,000, reflecting Medicare Advantage (MA) members of 431,000 to 441,000 amid ongoing optimization.
• FY 2026 outlook targets breakeven adjusted EBITDA, with full-year revenue of $5.41 billion to $5.58 billion.
• Historical earnings show revenue beats in recent quarters but EPS misses, leading to volatile stock reactions.

Earnings Context and Why It Matters

agilon health, a physician enablement company focused on Medicare Advantage and accountable care organization (ACO) models, faces scrutiny amid membership declines and elevated medical costs. FY 2025 revenue fell 2% to $5.93 billion, with a net loss of $391 million driven by a negative medical margin of $57 million. Q1 2026 earnings, due May 6 after market close, will test the company's transformation efforts, including cost reductions and payer contract improvements. For investors, this report signals potential profitability amid industry headwinds like CMS rate changes and cost trends around 7.5%. A positive outcome could validate the path to breakeven in 2026, boosting confidence in the stock's recovery post-reverse split.

Earnings Expectations

Analysts anticipate Q1 2026 revenue of $1.38 billion, per Yahoo Finance data from 16 analysts, while MarketBeat shows $1.5 billion consensus against company guidance of $1.35 billion to $1.39 billion. EPS estimates vary, with MarketBeat at $0.75 from two analysts, reflecting optimism for narrowing losses. agilon health's own guidance highlights medical margin of $115 million to $130 million and adjusted EBITDA of $35 million to $45 million, prioritizing operational leverage over top-line growth.

Investors will watch medical cost ratio (MCR), membership stability, and updates on prior-year development (PYD). Historically, Q1 2025 saw revenue beat estimates ($1.53 billion vs. $1.50 billion) and EPS surprise positively, though recent quarters like Q4 2025 featured revenue beats but EPS shortfalls, contributing to stock volatility.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Heading into Q1 earnings, sentiment is cautiously optimistic, buoyed by Q4 guidance for positive EBITDA despite FY 2025 losses. The stock has shown sharp reactions historically: Q4 2025 revenue beat lifted shares initially, but EPS miss pressured them amid membership contraction. Key risks include higher-than-expected medical costs or membership attrition beyond guidance. Analysts maintain a mix of holds and buys, with focus on execution against cost-saving OPEX reductions of $35 million.

Forward Outlook and Key Factors to Monitor

Post-Q1, investors should track progress toward FY 2026 guidance of $5.41 billion to $5.58 billion in revenue and breakeven adjusted EBITDA. Membership optimization remains critical, with MA lives projected at 425,000 to 435,000 for the year, down from 511,000 in 2025 due to exits and payer shifts but offset by new no-downside agreements.

Medical cost trends around 7.5% gross (7% net) will be pivotal, alongside CMS final 2027 rates (9%+ increase benefiting 2026) and payer bid outcomes improving margins by 50 basis points. Part D exposure below 15% reduces volatility, while ACO REACH performance could add $20 million to $25 million in EBITDA.

Upcoming catalysts include Q2 results validating Q1 momentum, geography entry costs at $15 million annually, and SG&A discipline. Broader Medicare Advantage dynamics, like star ratings (75% of members in 4+ star plans), will influence incentives. Balanced monitoring of these factors provides insight into sustained profitability without assuming outcomes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations